Secukinumab: promising new drug for ankylosing spondylitis

A drug – secukinumab – being explored as a treatment for ankylosing spondylitis showed sustained improvements in signs and symptoms of the condition in people who completed three years of treatment, according to data presented at the American College of Rheumatology Annual Meeting. Secukinumab also had a “favourable” safety profile consistent with previous reports.”

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.